Product Theater – Changes Impressions of Topical Therapy: Duobrii Lotion
Featuring Larry Green, MD
Dr. Larry Green presented a new medication for the treatment of psoriasis that will soon be released in the US. Duobrii is a once daily topical emulsion lotion that is FDA approved for the treatment of psoriasis. Dr. Green reports when psoriasis patients are surveyed, 100% have used topical treatments, while 93% are open to trying new treatments. This new medication contains the ingredients halobetasol propionate, a topical corticosteroid, and tazorotene, a receptor selective retinoid. Halobetasol exerts an anti -inflammatory, anti-pruritic, anti-proliferative and vasoconstrictive effect. While tazarotene was originally formulated for use in the treatment of psoriasis, its use has been limited by irritation. The AAD recommends combination with steroids to mitigate this irritation. According to Dr. Green, the two ingredients in this medication work synergistically for the treatment of psoriasis.
This new medication contains the ingredients halobetasol propionate, a topical corticosteroid, and tazorotene, a receptor selective retinoid.
Dr. Green reports Duobrii has an efficient epidermal delivery system of hydrating ingredients. When patients were treated with the combination medication of Duobrii, vs either of the ingredients of the medication alone, patients had better treatment success with Duobrii. One of the benefits of Duobrii, according to Dr. Green, is the ‘improved skin barrier function’ or the ability to ‘keeps water in the skin’. Additionally the addition of the retinoid ingredient is it’s lasting effects. The most common adverse event of Duobrii is contact dermatitis. Duobrii is contraindicated for treatment during pregnancy.
Byline: Sarah Patton, MSHS, PA-C
Posted: June 7, 2019